HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Regulation Europe Cosmetic Ingredients

EU To Provide Guidance On New Endocrine Disruptor, Persistent Chemicals Hazard Classes In 2024

  • News

Executive Summary

Industry should use existing guidance for the identification of endocrine disruptors until the European Chemicals Agency updates Guidance on the Application of the CLP Criteria, targeted for mid-2024. Transition periods will begin elapsing in May 2025 when new substances on the market must be compliant with the new hazard communication requirements, followed by new mixtures in May 2026.

Table

View full table

Related Content

HBW Insight

Topics

Tags:
Regulation Europe Cosmetic Ingredients
Latest Headlines

Beiersdorf Partners With Biopharma For Anti-Aging Skin Care Innovation; Beauty Business News

Clasado, Probi Funded Study Shows Synergistic Effect Of Synbiotic Combination

Qunol Acquisition Gets Sanofi CHC Off To Flying Start

Walmart Lays Out Expectations For Beauty Brands' MoCRA Compliance

See All
UsernamePublicRestriction

Register

RS153643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By